We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Close-run thing

7 November 2014 By Robert Cyran

Earlier this year, the pharma company was pursuing Allergan, which was chasing Salix, which had agreed to buy Cosmo. Such frenzied deal-making encourages puffery. Allergan avoided falling for Salix, which just admitted channel-stuffing, but is still vulnerable to dubious Valeant.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)